GWS
RPRX icon

Glassman Wealth Services’s Royalty Pharma RPRX Stock Holding History

Glassman Wealth Services’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-674
Closed -$18.9K – 1481
2023
Q4 		$18.9K Buy
+674
New +$18.5K ﹤0.01% 702
2021
Q3 		– Sell
-599
Closed -$25K – 1772
2021
Q2 		$25K Buy
+599
New +$25.5K 0.01% 515
2021
Q1 		– Sell
-451
Closed -$23K – 1604
2020
Q4 		$23K Buy
+451
New +$19.1K 0.01% 493

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Glassman Wealth Services's RPRX Position: Q1 2024 in Review

Glassman Wealth Services sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 674 shares — an estimated $18.9K sold.

Glassman Wealth Services first reported a position in RPRX in Q4 2020 and held it in 3 quarters. The position peaked at $25K in Q2 2021. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Glassman Wealth Services reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 674 Royalty Pharma shares in Q1 2024, an estimated $18.9K.
  • Glassman Wealth Services first reported a position in Royalty Pharma in Q4 2020 and held it in 3 quarters.
  • Glassman Wealth Services's Royalty Pharma position peaked at $25K in Q2 2021.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.